mRNA vaccine

Moderna and other companies are developing an mRNA vaccine to combat the Bundibugyo virus, which is driving the current Ebola outbreak. The effort focuses on addressing the rare virus causing the ongoing epidemic.

A personalized mRNA vaccine developed by Moderna and Merck shows promise in reducing the recurrence of melanoma, the deadliest form of skin cancer, according to a five-year follow-up of a Phase 2b study.

A study found an mRNA vaccine highly effective in preventing melanoma recurrence when combined with Keytruda, an immunotherapy drug. The vaccine targets this dangerous skin cancer using personalized mRNA technology.

A study found that an mRNA vaccine is highly effective at preventing recurrence of melanoma when used in combination with Keytruda, an immunotherapy drug.

An experimental mRNA vaccine has shown in rodent tests to provide protection against three strains of the Ebola virus, including the strain currently causing a crisis. The vaccine is in development and has not yet been tested in humans.

Moderna and Korea University have been developing a new mRNA vaccine for hantavirus since 2023, showing promising results but no finished product is expected soon. The development is ongoing, with the goal of creating an effective vaccine against hantavirus. Further research is needed to bring the vaccine to market.

An experimental personalized mRNA vaccine for pancreatic cancer has shown major promise, with the first recipient at Memorial Sloan Kettering now cancer-free for six years. The treatment, highlighted by NBC News' Anne Thompson, could represent a breakthrough for patients.

An mRNA vaccine for pancreatic cancer has shown lasting results in an early clinical trial, offering potential new treatment options. The trial's success highlights the vaccine's ability to target the disease effectively.